Naloxone
naloxone hydrochloride — Narcan (nasal spray, OTC), Kloxxado (nasal spray, Rx), Zimhi (SC injection), generic injectable
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Emergency treatment of known or suspected opioid overdose manifested by respiratory and/or CNS depression (all formulations) | Adults and paediatric patients (including neonates) | Emergency reversal | FDA Approved |
| Complete or partial reversal of opioid depression induced by natural, synthetic, or semi-synthetic opioids — including respiratory depression (injectable) | Adults and paediatric patients | Reversal / titration | FDA Approved |
| Diagnosis of suspected acute opioid overdose (injectable) | Adults | Diagnostic challenge | FDA Approved |
Naloxone is the primary pharmacological antidote for opioid overdose and has been in clinical use since FDA approval in 1971. It is a pure competitive antagonist at opioid receptors with no intrinsic agonist activity, meaning it produces no pharmacological effect in the absence of exogenous or endogenous opioids. The landmark approval of Narcan 4 mg nasal spray as an over-the-counter (OTC) product in March 2023 represented a major public health advance, dramatically expanding community access to this life-saving medication. Naloxone is not a substitute for emergency medical care — all patients who receive naloxone for suspected overdose should be transported to an emergency department, as the duration of action of many opioids exceeds that of naloxone, creating risk of re-narcotisation.
Adjunct in septic shock — High-dose naloxone has been investigated as a vasopressor in refractory septic shock; transient blood pressure increases observed but no demonstrated survival benefit. Evidence quality: Low.
Opioid-induced pruritus — Low-dose naloxone infusion (0.25–1 mcg/kg/h) to treat opioid-mediated itching while preserving analgesia. Evidence quality: Moderate.
Opioid-induced constipation (enteral) — Enteral naloxone exploits low oral bioavailability to block intestinal opioid receptors without reversing systemic analgesia. Evidence quality: Moderate.
Dosing
Adult Dosing — By Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Community opioid overdose — layperson rescue (IN) | 4 mg IN one nostril (Narcan) | Repeat q2–3 min in alternate nostril | No upper limit in emergency | OTC; no assembly required; administer in supine position with head tilted back Kloxxado 8 mg IN available for settings with high-potency synthetic opioid exposure (FDA PI) |
| Hospital opioid overdose — emergency reversal (IV/IM/SC) | 0.4–2 mg IV q2–3 min | Repeat q2–3 min until response | 10 mg total | If no response after 10 mg total, reassess diagnosis (consider non-opioid cause) IV onset ~2 min; IM onset ~2–5 min; IM produces more prolonged effect (FDA PI) |
| Post-operative opioid reversal — titrated (IV) | 0.1–0.2 mg IV q2–3 min | Titrate to respiratory rate ≥12 (not consciousness) | Titrate to effect | Goal: restore ventilation without fully reversing analgesia or precipitating withdrawal May dilute 0.4 mg in 10 mL NS (0.04 mg/mL) for precise titration |
| Opioid-dependent patient — cautious reversal (IV) | 0.04–0.08 mg IV q30–60 sec | Titrate to respiratory effort | Titrate to effect | Dilute 0.4 mg in 10 mL NS to 0.04 mg/mL; aim for respiratory rate ≥12, not full arousal Minimise precipitated withdrawal; may use 0.02 mg (20 mcg) increments in cancer pain (APS 2008) |
| Continuous infusion — sustained reversal (IV) | Two-thirds of effective bolus dose per hour | 0.2–0.6 mg/h typical; adjust PRN | Titrate to effect | Give half the initial bolus dose 15 min after starting infusion to prevent level drop Dilute in D5W or NS; indicated when opioid t½ exceeds naloxone t½ (e.g., methadone, ER formulations) |
| High-potency synthetic opioid exposure (fentanyl analogues) | 8 mg IN one nostril (Kloxxado) or 5 mg SC (Zimhi) | Repeat as needed q2–3 min | No upper limit in emergency | Higher initial doses may be necessary for potent synthetic opioids Zimhi 5 mg SC auto-injector designed for community use with thigh injection |
Paediatric & Neonatal Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Paediatric opioid overdose (≥20 kg or ≥5 years) | 0.1 mg/kg IV/IM (max 2 mg) | Repeat q2–3 min | 10 mg total | Full reversal dose; IN Narcan 4 mg also FDA-approved for paediatric use AAP does not endorse SC/IM in opiate intoxication due to erratic absorption |
| Neonatal opioid depression (post-delivery) | 0.01 mg/kg IV/IM/SC | Repeat q2–3 min | Titrate to effect | Neonatal t½ ~3.1 h (longer than adults); monitor ≥24 h post-dose Administer directly to neonate; not via mother. No benefit in non-opioid-related intrauterine asphyxia (FDA PI) |
| Post-operative paediatric reversal (IV) | 0.005–0.01 mg/kg IV q2–3 min | Titrate to respiratory rate | Titrate to effect | Low-dose titration to preserve analgesia Weight-based dosing essential in paediatric patients |
Naloxone’s duration of action (30–90 minutes) is shorter than that of most opioids. Patients who respond to naloxone may relapse into respiratory depression as naloxone is metabolised, particularly with long-acting opioids (methadone t½ 8–59 h; fentanyl patches; buprenorphine t½ 20–73 h) or after large opioid ingestions. All patients must be monitored for at least 2 hours after last naloxone dose; patients exposed to long-acting opioids require monitoring for 6–12 hours or longer. Continuous naloxone infusion may be required.
In post-operative and opioid-dependent settings, the goal of naloxone is to restore adequate spontaneous ventilation (respiratory rate ≥12 breaths/min), not to achieve full alertness. Full reversal in opioid-dependent patients precipitates severe withdrawal and does not improve outcomes. Dilute 0.4 mg naloxone in 10 mL normal saline (0.04 mg/mL) and administer in 1 mL (0.04 mg) increments for precise titration.
Pharmacology
Mechanism of Action
Naloxone is a semi-synthetic opioid antagonist derived from oxymorphone (specifically 17-allyl-4,5-epoxy-3,14-dihydroxymorphinan-6-one). It acts as a competitive antagonist at mu-, kappa-, and delta-opioid receptors, with highest affinity for the mu-receptor. Naloxone has no intrinsic agonist activity and produces no pharmacological effect in the absence of opioids. When administered in the presence of opioid agonists, naloxone rapidly displaces the agonist from receptor binding sites, reversing respiratory depression, sedation, and miosis within minutes. The speed and completeness of reversal depend on the binding characteristics of the opioid being antagonised: opioids with rapid receptor dissociation kinetics (e.g., morphine) are reversed more quickly and completely than those with slow dissociation (e.g., buprenorphine, which requires substantially higher naloxone doses for reversal). Naloxone also blocks endogenous opioid peptides (endorphins, enkephalins), which explains its ability to precipitate acute withdrawal in opioid-dependent individuals and its capacity to block placebo-mediated analgesia.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | IV onset ~2 min; IM/SC onset 2–5 min; IN onset ~5–10 min (Tmax 15–30 min); oral bioavailability <5% (extensive hepatic first-pass); IN bioavailability ~50% vs IM (dose-normalised) | IV is fastest onset for hospital reversal; IN suitable for community use with comparable efficacy; oral route not viable for systemic effect but exploited for enteral opioid receptor blockade (e.g., opioid-induced constipation) |
| Distribution | Vd ~200 L; rapidly distributed; readily crosses placenta; weak plasma protein binding (primarily albumin) | Rapid distribution into CNS enables fast reversal; crosses placenta — can precipitate withdrawal in opioid-exposed foetus; low protein binding means displacement interactions are unlikely |
| Metabolism | Hepatic glucuronide conjugation → naloxone-3-glucuronide (major, inactive); minor N-dealkylation and reduction; metabolites are pharmacologically inactive | All metabolites inactive — no active metabolite concerns; rapid clearance (~2,500 L/day) explains short duration of action; no CYP450 involvement — minimal drug interaction potential from metabolic pathway |
| Elimination | t½ 30–81 min IV/IM (mean 64 ± 12 min); IN t½ ~2 h; neonatal t½ 3.1 ± 0.5 h; renal excretion: 25–40% in 6 h, 50% in 24 h, 60–70% in 72 h (as metabolites) | Short t½ is the primary clinical limitation — opioid effects may outlast naloxone, requiring repeat dosing or continuous infusion; IN formulations achieve longer t½ (~2 h) due to depot effect in nasal mucosa; neonatal t½ is ~5x longer than adult, requiring extended monitoring |
Side Effects
Naloxone has essentially no adverse effects in opioid-naive individuals. Most reported “adverse effects” represent precipitated opioid withdrawal or physiological responses to abrupt reversal of opioid-mediated CNS/respiratory depression. The side effect profile below reflects both intrinsic drug effects (studied in healthy volunteers) and withdrawal-related effects observed in clinical practice.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea / Vomiting | Common withdrawal symptom | Place patient in recovery position to reduce aspiration risk; not a naloxone drug effect per se but a consequence of withdrawal |
| Tachycardia / Hypertension | Common withdrawal symptom | Catecholamine surge from abrupt opioid reversal; increased risk in patients with pre-existing cardiac disease |
| Diaphoresis / Piloerection | Common withdrawal symptom | Autonomic response; self-limiting after opioid re-equilibration |
| Agitation / Restlessness / Tremor | Common withdrawal symptom | May require verbal de-escalation; avoid physical restraint; may indicate excessive reversal |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Increased blood pressure | Reported in PK studies | Observed in healthy volunteers receiving Narcan IN; likely pharmacological effect |
| Headache | 3.7% (IN study) | Common across both IN and injectable formulations in PK studies |
| Nasal symptoms (IN formulations) | Reported in PK studies | Nasal dryness, congestion, edema, inflammation, rhinalgia — local effects of intranasal delivery |
| Musculoskeletal pain / Muscle spasms | Reported in PK studies | Observed in healthy volunteers receiving Narcan IN |
| Dizziness | Reported in PK studies | Reported with both Kloxxado 8 mg and injectable formulations |
| Injection site erythema (injectable) | Reported in PK studies | Local reaction at injection site; transient |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Precipitated opioid withdrawal syndrome | Expected in opioid-dependent patients | Within minutes of administration | Supportive care; can be minimised by titrating to ventilation, not consciousness; in opioid-dependent patients, use lowest effective dose |
| Pulmonary oedema (non-cardiogenic) | Rare | Minutes to hours post-reversal | Supportive ventilation; diuretics; ICU monitoring; mechanism: centrally mediated massive catecholamine surge shifting blood volume to pulmonary vascular bed |
| Ventricular tachycardia / Fibrillation / Cardiac arrest | Rare (post-marketing) | Minutes post-reversal | ACLS protocols; more likely in patients with cardiac disease or concurrent stimulant use (e.g., cocaine); catecholamine surge may trigger dysrhythmias in hypoxic myocardium |
| Seizures | Rare (post-marketing) | Minutes post-reversal | Benzodiazepines; supportive care; may be related to withdrawal or underlying pathology |
| Severe hypertension | Uncommon | Minutes post-reversal | Antihypertensive management if sustained; associated with abrupt full reversal in post-operative or opioid-dependent settings |
Naloxone is used as a single-dose or short-term emergency intervention, not as a maintenance medication. Discontinuation considerations do not apply. However, patients who receive naloxone for opioid overdose should be counselled on the risk of re-overdose and referred to addiction treatment services when appropriate.
Drug Interactions
Naloxone has a remarkably clean pharmacokinetic interaction profile. It is metabolised by glucuronide conjugation (not CYP450), does not inhibit or induce hepatic enzymes, and has weak protein binding. Its interactions are almost entirely pharmacodynamic, arising from its role as an opioid receptor antagonist.
Monitoring
- Respiratory Rate & SpO2Continuous until stable
RoutinePrimary endpoint of naloxone therapy. Target ≥12 breaths/min and SpO2 ≥92%. Monitor continuously during and after reversal. Re-narcotisation risk highest 30–120 min after last naloxone dose. - Level of Consciousnessq5–15 min post-dose
RoutineDeclining consciousness after initial response indicates re-narcotisation. GCS scoring. In post-operative settings, aim for respiratory adequacy, not full alertness. - Cardiac Rhythm & Vital SignsContinuous during reversal
RoutineMonitor for tachycardia, hypertension, arrhythmias. Particular risk with cardiac disease, pre-existing hypoxia, or concurrent stimulant use. Post-marketing reports of VT/VF and cardiac arrest. - Withdrawal SignsThroughout reversal
Trigger-basedSigns: piloerection, diaphoresis, rhinorrhoea, tachycardia, agitation, abdominal cramps, diarrhoea. In opioid-dependent patients, titrate to respiratory effort not full reversal. Neonatal withdrawal may include seizures, excessive crying, hyperactive reflexes. - Observation PeriodMinimum 2 h (short-acting opioids); 6–12+ h (long-acting)
RoutineDuration depends on opioid involved. Short-acting (heroin, morphine): minimum 2 h. Long-acting (methadone, fentanyl patch, buprenorphine, ER formulations): minimum 6–12 h. Children: monitor ≥24 h as relapses may occur (FDA PI). - Pulmonary AssessmentIf dyspnoea develops post-reversal
Trigger-basedAssess for non-cardiogenic pulmonary oedema; CXR if clinically indicated. Mechanism: centrally mediated catecholamine surge. Manage with supportive ventilation and diuretics if needed.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to naloxone hydrochloride or any excipients
Relative Contraindications (Specialist Input Recommended)
- Known opioid dependence without respiratory compromise — administering naloxone will precipitate severe withdrawal; in non-emergency situations, use lowest dose and titrate carefully
- Known cardiac disease — abrupt reversal may trigger catecholamine surge causing tachycardia, hypertension, VT/VF in vulnerable myocardium
- Concurrent stimulant overdose (cocaine, methamphetamine) — reversal of opioid-mediated sedation may unmask stimulant-mediated cardiovascular toxicity
Use with Caution
- Pregnancy (opioid-dependent mother) — may precipitate withdrawal in foetus; use if maternal life-threatening emergency; have neonatal team available
- Post-surgical patients — full reversal eliminates analgesia and may cause severe pain, hypertension, and pulmonary oedema; titrate carefully
- Neonates of opioid-dependent mothers — may precipitate withdrawal including seizures; neonatal t½ is ~3.1 h requiring extended monitoring
- Renal or hepatic impairment — safety not formally established; given emergency use and short half-life, benefit outweighs risk in overdose
In the context of suspected life-threatening opioid overdose with respiratory depression, naloxone should always be administered regardless of allergy history, dependency status, or comorbidities. The risk of death from untreated respiratory depression far outweighs any potential adverse effect. Hypersensitivity to naloxone is the only formal FDA-listed contraindication, and even this would be overridden in a life-threatening scenario with appropriate anaphylaxis management prepared.
Patient Counselling
Purpose of Therapy
Naloxone is an emergency medication that rapidly reverses the life-threatening effects of opioid overdose, particularly the dangerously slowed breathing that can cause death. It works by blocking the opioid from acting on receptors in the brain. Naloxone has been available by prescription since 1971 and the Narcan 4 mg nasal spray became available without a prescription (over-the-counter) in 2023. Having naloxone available does not encourage drug use — it prevents death, giving individuals the opportunity to access treatment.
Who Should Carry Naloxone
Anyone prescribed opioid medications (especially at higher doses, with concurrent benzodiazepines, or with history of overdose), family members or household contacts of individuals using opioids, and individuals using illicit opioids should have naloxone readily available. Many pharmacies dispense naloxone without a prescription. Community naloxone distribution programmes are available in most areas.
Sources
- Narcan (naloxone hydrochloride) nasal spray — Full prescribing information (Emergent BioSolutions). DailyMed. DailyMedPrimary reference for Narcan 4 mg nasal spray dosing, PK data (bioavailability vs IM), and adverse reactions from healthy volunteer studies.
- Kloxxado (naloxone hydrochloride) nasal spray — Full prescribing information. FDA/Drugs@FDA. FDA LabelSource for 8 mg high-dose nasal spray formulation, PK comparison with 4 mg IN and 0.4 mg IM, and high-potency opioid exposure guidance.
- Naloxone hydrochloride injection — Full prescribing information. DailyMed (Hospira/Pfizer). DailyMedInjectable formulation reference for IV/IM/SC dosing across all populations (adult, paediatric, neonatal), post-operative reversal, and PK parameters.
- Saari TI, Strang J, Dale O. Clinical pharmacokinetics and pharmacodynamics of naloxone. Clin Pharmacokinet. 2024;63(4):397–422. doi:10.1007/s40262-024-01360-9Comprehensive 2024 PK/PD review covering all formulations, simulated dosing schemes for nasal sprays, and receptor kinetics of reversal.
- Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146–155. doi:10.1056/NEJMra1202561Landmark NEJM review of opioid overdose management establishing the titration-to-ventilation approach and continuous infusion protocol.
- Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9(1):63–88. doi:10.1177/2042098617744161Comprehensive dosing review covering IV bolus, continuous infusion, weight-based paediatric dosing, and opioid-dependent patient titration strategies.
- Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association guidelines update. Circulation. 2015;132(18 Suppl 2):S501–S518. doi:10.1161/CIR.0000000000000264AHA guideline for opioid-associated emergencies establishing naloxone use within cardiac arrest and peri-arrest protocols.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(RR-3):1–95. doi:10.15585/mmwr.rr7103a1CDC guideline recommending naloxone co-prescribing for patients at elevated overdose risk, including those on ≥50 MME/day or with concurrent benzodiazepines.
- Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020;14(2S Suppl 1):1–91. doi:10.1097/ADM.0000000000000633ASAM guideline recommending naloxone prescriptions for all patients receiving opioid agonist therapy and their household contacts.
- Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the reversal of buprenorphine-induced respiratory depression by naloxone. Clin Pharmacokinet. 2007;46(11):965–980. doi:10.2165/00003088-200746110-00004PK/PD model demonstrating the difficulty of reversing buprenorphine with naloxone due to slow receptor dissociation kinetics.
- Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008;30(4):490–496. doi:10.1097/FTD.0b013e3181816214Population PK study establishing Vd (~200 L), clearance, and comparative bioavailability across IV, IM, and IN routes.
- Jordan MR, Patel P, Morrisonponce D. Naloxone. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 May 5. NCBI BookshelfStatPearls reference covering naloxone pharmacology, all administration routes, OTC status, and community naloxone distribution initiatives.
- FDA approves first over-the-counter naloxone nasal spray. FDA News Release, 29 March 2023. FDA.govOfficial FDA announcement of Narcan 4 mg nasal spray OTC approval, the first naloxone product available without a prescription in the US.